Mr. Carl A Cheramie, CRNA Nurse Anesthetist, Certified Registered Medicare: Accepting Medicare Assignments Practice Location: 1097 Northwest Blvd, Franklin, LA 70538 Phone: 337-828-0760 Fax: 337-828-5024 |
News Archive
Tumor cells divide fast. They thus require a high supply of components for their DNA, like purines. The biosynthesis of purines could now be a new point of attack for chemotherapy. However, without a natural model, the search for an inhibitor for a cellular process is like the proverbial search for a needle in a haystack. An American research team has developed a clever way to quickly conjure the desired "needle" out of the hay, presenting several candidates to act as starting points for the design of a purine synthesis inhibitor.
Imiquimod is a medication successfully used in the treatment of skin diseases. In addition to its known mechanism of action, it also triggers other processes in the body.
Researchers at University of California San Diego School of Medicine and Arizona State University have received funding from The Michael J. Fox Foundation for Parkinson's Research to launch a multi-year, $1.7-million effort to identify blood-based biomarkers of Parkinson's disease, which could improve care and accelerate new treatments for the neurodegenerative disorder, which affects nearly 1 million Americans, with 60,000 new cases diagnosed annually.
Scientists are making strides toward unraveling the surprisingly complex chemistry underpinning that axiom of infant feeding "breast is best," according to an article in the current edition of Chemical & Engineering News.
Researchers at Johns Hopkins Medicine have identified in live human brains new radioactive "tracer" molecules that bind to and "light up" tau tangles, a protein associated with a number of neurodegenerative diseases including Alzheimer's disease and other related dementias.
› Verified 7 days ago